Global Antifungal Drugs Market Report and Forecast 2025-2034

Global Antifungal Drugs Market Outlook

The global antifungal drugs market value was USD 15.35 billion in 2024, driven by the increasing prevalence of fungal infections across the globe. The global antifungal drugs market share is anticipated to grow at a CAGR of 3.7% during the forecast period of 2025-2034 to achieve a value of USD 21.28 billion by 2034.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Significant Growth of the Azoles Segment to Bolster the Growth of the Antifungal Drugs Industry

Based on drug class, the azoles segment accounts for a significant share in the market and is anticipated to witness a considerable growth in the forecast period. Azoles are used to treat a wide range of conditions, including yeast infection, tinea versicolor, and athlete's foot, and are available in different formulations, such as capsules, lotions, and sterile IV solutions, among others. These drugs offer improved absorption and distribution properties with fewer side effects and less serious drug interactions.

These factors have been contributing to the growth of the segment. Over the forecast period, the rising demand for azoles in combination with other antifungal agents to treat systematic and superficial fungal infections is likely to be a major factor driving the market. In addition to this, the growing cases of candidemia, blastomycosis, systematic candidiasis, and ocular fungal infections, among others are likely to aid the segment growth in the coming years.

North America Accounts for a Significant Share in the Antifungal Drugs Industry

North America accounts for a significant market share in the antifungal drugs industry due to the improved healthcare infrastructure, rise in echinocandin resistance, and the growing cases of fungal infections in the region.  The growing pharmaceutical industry and the presence of the leading companies in the region are supporting the market growth in North America. Moreover, the increasing commercialisation of drugs is expected to further contribute to the antifungal drugs industry growth in the region.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Antifungal Drugs: Market Segmentation

Antifungal drugs can be defined as a type of drug that helps eliminate fungal infection from the body with minimum toxic side effects. Antifungal drugs basically act against fungal pathogens and are used in the treatment of fungal infections.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on drug class, the market is segmented into:

• Azoles 
  • Voriconazole 
  • Posaconazole 
  • Isavuconazole (CRESEMBA) 
  • Others 
• Echinocandins 
  • Caspofungin 
  • Micafungin (Mycamine/ Funguard) 
  • Others 
• Polyenes 
  • Amphotericin (AmBisome) 
  • Others 
• Allylamines 
  • Terbinafine
  • Others
• Others 

On the basis of indication, the industry is divided into:

• Dermatophytosis 
• Aspergillosis 
• Candidiasis 
  • Invasive Candidiasis 
  • Vulvovaginal Candidiasis (VVC) 
  • Mouth/Throat/Esophageal Candidiasis 
  • Others 
• Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Growing Risk of Fungal Infections to Boost the Growth of the Antifungal Drugs Industry

The global market for antifungal drugs is driven by the growing prevalence of fungal infections across the globe. The increasing consumption of unhealthy food, which might compromise the immune system, is likely to increase the risk of fungal infections, which, in turn, is expected to propel the demand for antifungal drugs. Furthermore, the rising geriatric population,  which is more susceptible to fungal infections such as ringworm, candidiasis, and systematic mycosis, among others, is significantly contributing to the market growth.

Over the forecast period, the growing investments by the leading pharmaceutical companies to develop novel and more effective drugs for fungal diseases are anticipated to augment the market growth in the forecast period.

Key Industry Players in the Global Antifungal Drugs Market

The report gives a detailed analysis of the following key players in the global antifungal drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Abbott Laboratories
• GlaxoSmithKline PLC
• Novartis AG
• Pfizer Inc.
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report